EL
RANI icon

EWA LLC’s Rani Therapeutics RANI Stock Holding History

EWA LLC’s Portfolio RANI Stock Details RANI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8K Sell
10,520
-297
-3% -$263 ﹤0.01% 330
2026
Q1 		$7.95K Sell
10,817
-264
-2% -$337 ﹤0.01% 281
2025
Q4 		$15K Buy
+11,081
New +$16.7K ﹤0.01% 263

Other funds holding RANI

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LP
Longaeva Partners Chicago, Illinois $4.58B AUM 43.91% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

EWA LLC's RANI Position: Q2 2026 in Review

EWA LLC reduced its Rani Therapeutics (RANI) stake by 2.7% in Q2 2026, selling an estimated $263 and leaving 10,520 shares worth $8K. The position accounts for ﹤0.01% of the portfolio, ranked #330.

EWA LLC first reported a position in RANI in Q4 2025 and has held it in 3 quarters since. The position peaked at $15K in Q4 2025. 67 funds tracked by Wall St. Rank hold RANI as of Q2 2026.

  • EWA LLC held 10,520 shares of Rani Therapeutics worth $8K as of Q2 2026.
  • EWA LLC sold 297 Rani Therapeutics shares in Q2 2026, an estimated $263.
  • Rani Therapeutics made up ﹤0.01% of EWA LLC's portfolio in Q2 2026, its #330 holding.
  • EWA LLC first reported a position in Rani Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • EWA LLC's Rani Therapeutics position peaked at $15K in Q4 2025.
  • 67 funds tracked by Wall St. Rank held Rani Therapeutics as of Q2 2026.

Based on EWA LLC's 13F filing for Q2 2026, filed 14 Jul 2026.